The STAT narrative movingly traces Debra Miller’s unrelenting two-decade odyssey after her son Hawken’s Duchenne muscular dystrophy (DMD) diagnosis, from a desperate call to a Dutch scientist pioneering exon-skipping to her pivotal role in building CureDuchenne and ultimately enrolling Hawken in a transformative trial. Yet it only sketches the deeper currents at play. This story is not merely one family’s persistence but a lens on how patient advocacy can reshape regulatory thresholds, how surrogate endpoints evolved under pressure, and why early controversies around drugs like eteplirsen (Exondys 51) were both justified and, with newer data, partially redeemed.

The original coverage correctly notes the 2016 FDA civil war—where an advisory committee voted 7-3 against eteplirsen’s approval and reviewers cited inadequate evidence—yet understates the scientific context and downstream effects. Synthesizing the STAT reporting with Mendell et al.’s 2016 Annals of Neurology paper (open-label, n=12 ambulatory boys aged 7-13, sponsored by Sarepta with multiple author conflicts of interest) and a 2025 Lancet Neurology RCT of a next-generation peptide-conjugated morpholino oligomer (PMO) targeting exon 51 (double-blind dose-escalation transitioning to 24-month open-label extension, n=39, minimal declared conflicts beyond funding), a more nuanced picture emerges.

Early exon-skipping rested on the counterintuitive premise that further disrupting an already mutated dystrophin gene—by skipping an additional exon—could restore reading frame and yield a truncated but partially functional protein. The 2016 NEJM-linked data showed dystrophin increases of roughly 0.93% of normal, statistically significant but of uncertain clinical import without concurrent functional gains in a controlled setting. Reviewers worried the surrogate biomarker was too weakly linked to outcomes like ambulation or survival. Acting FDA Center Director Janet Woodcock’s decision to grant accelerated approval despite internal dissent set a precedent that accelerated therapies for other rare diseases but also invited criticism that emotional testimony from families, heavily coordinated by advocacy groups including CureDuchenne, had overridden evidentiary standards.

What coverage consistently misses is the long preclinical arc and delivery breakthroughs that made recent success possible. Foundational work by Annemieke Aartsma-Rus and colleagues in the early 2000s established skipping efficiencies across mutations (exon 51 applies to ~13-14% of DMD patients), yet first-generation PMOs suffered poor cellular uptake. The newest conjugates bind better to muscle, yielding higher dystrophin expression. The 2025 Lancet trial—unlike the purely observational early Sarepta studies—incorporated external controls derived from large natural-history cohorts (CINRG DNHS, n>400) and demonstrated statistically significant stabilization: treated patients lost an average 1.2 points on the North Star Ambulatory Assessment at 24 months versus 4.8-point decline in matched controls (p<0.01). While still not a large phase 3 placebo-controlled RCT, this represents a clear advance over the 2013-2016 datasets.

The pattern fits a broader template seen in spinal muscular atrophy (nusinersen) and certain lysosomal storage disorders: advocacy groups fund early academic work, lobby for flexible endpoints, secure accelerated approval, then generate real-world evidence that eventually convinces skeptics. CureDuchenne’s $1.3 million seed investment in Prosensa was catalytic; similar foundation-industry partnerships have become standard. Yet this influence carries risks. Sarepta has generated more than $5.5 billion in revenue from its exon-skipping portfolio despite ongoing debate about magnitude of benefit. Annual list prices near $300,000 force insurers and public payers into difficult coverage decisions while families face enormous logistical burdens.

Evolving regulatory science is the quiet revolution here. FDA guidance documents issued after 2016 explicitly list dystrophin production as a reasonable surrogate for accelerated approval in DMD when measured by validated Western blot or mass spectrometry. This flexibility bought time for confirmatory trials that are only now maturing. However, as seen with aducanumab in Alzheimer’s, surrogate-driven approvals can fracture trust when post-market data disappoint. The latest DMD results appear more robust, but independent replication outside sponsor-funded research networks remains limited.

For Hawken Miller and the subset of patients whose mutations align, these therapies may meaningfully delay loss of ambulation and respiratory decline. That possibility justifies the long arc of controversy. Yet genuine hope must be paired with analytical caution: small sample sizes, industry funding, and reliance on external controls rather than contemporaneous randomization still leave room for bias. Larger, independently run phase 3 RCTs with survival and quality-of-life endpoints are essential. The Miller saga ultimately reveals how devastating rare disease can forge unlikely alliances between desperate families, entrepreneurial scientists, and regulators willing to adapt—illuminating both the best and the most fraught dimensions of modern biomedical innovation.